Marija Milković Periša

Prof. Marija Milković Periša

School of Medicine, University of Zagreb, Zagreb, Zagreb, Grad, Croatia
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
BKBožo Krušlin
Božo Krušlin
DTDavor Tomas
Davor Tomas
TDTihana Džombeta
Tihana Džombeta
MPMarija Milković Periša
Marija Milković Periša
MUMonika Ulamec
Monika Ulamec
Chronic inflammation is associated with both benign conditions and cancer. Likewise, inflammatory cells are quite common in benign prostatic hyperplasia and prostatic tissue harboring cancer. Triggers which activate inflammatory pathways in the prostate remain a subject of argument and are likely to be multifactorial, some of these being bacterial antigens, different chemical irritations and metabolic disorders. Acute and chronic inflammation in prostate leads to accumulation of immunocompetent cells, mainly T lymphocytes and macrophages, but also neutrophils, eosinophils and mast cells, depending on the type of offending agent. Inflammatory processes activate hyperproliferative programs resulting in nodules seen in benign prostatic hyperplasia, but are also important in creating suitable microenvironment for cancer growth and progression. Inflammatory cells have mostly been shown to have a protumoral effect such as tumor associated macrophages, but some cell types such as mast cells, have antitumoral effects. This review outlines the recent findings and theories supporting the role of inflammatory responses as drivers of both benign and malignant epithelial processes in the prostate gland. Key words: inflammation, benign prostatic hyperplasia, prostatic carcinoma, inflammatory cells, cytokines

19 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JVJosip Vrdoljak
Josip Vrdoljak
ZBZvonimir Boban
Zvonimir Boban
DBDomjan Barić
Domjan Barić
DŠDarko Šegvić
Darko Šegvić
Marko KumricMarko Kumric
Marko Kumric
Josko BozicJosko Bozic
Josko Bozic
Background: Due to recent changes in breast cancer treatment strategy, significantly more patients are treated with neoadjuvant systemic therapy (NST). Radiological methods do not precisely determine axillary lymph node status, with up to 30% of patients being misdiagnosed. Hence, supplementary methods for lymph node status assessment are needed. This study aimed to apply and evaluate machine learning models on clinicopathological data, with a focus on patients meeting NST criteria, for lymph node metastasis prediction. Methods: From the total breast cancer patient data (n = 8381), 719 patients were identified as eligible for NST. Machine learning models were applied for the NST-criteria group and the total study population. Model explainability was obtained by calculating Shapley values. Results: In the NST-criteria group, random forest achieved the highest performance (AUC: 0.793 [0.713, 0.865]), while in the total study population, XGBoost performed the best (AUC: 0.762 [0.726, 0.795]). Shapley values identified tumor size, Ki-67, and patient age as the most important predictors. Conclusion: Tree-based models achieve a good performance in assessing lymph node status. Such models can lead to more accurate disease stage prediction and consecutively better treatment selection, especially for NST patients where radiological and clinical findings are often the only way of lymph node assessment.

31 December 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
TKTamara Kralj
Tamara Kralj
Antonio KokotAntonio Kokot
Antonio Kokot
MZMirna Zlatar
Mirna Zlatar
SMSanja Masnec
Sanja Masnec
KKKatarina Kasnik Kovac Kasnik Kovac
Katarina Kasnik Kovac Kasnik Kovac
PSPredrag Sikiric
Predrag Sikiric
Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats. If not upgraded, one episcleral vein is regularly unable to acquire and take over the whole function, and glaucoma-like features persist. Recently, the rapid upgrading of the collateral pathways by a stable gastric pentadecapeptide BPC 157 has cured many severe syndromes induced by permanent occlusion of major vessels, veins and/or arteries, peripherally and centrally. In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery). The daily regimen of BPC 157 (0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg) was administered locally as drops in each eye, intraperitoneally (last application at 24 h before sacrifice) or per-orally in drinking water (0.16 µg/mL, 0.16 ng/mL, 12 mL/rat until the sacrifice, first application being intragastric). Consequently, all BPC 157 regimens immediately normalized intraocular pressure. BPC 157-treated rats exhibited normal pupil diameter, microscopically well-preserved ganglion cells and optic nerve presentation, normal fundus presentation, normal retinal and choroidal blood vessel presentation and normal optic nerve presentation. As leading symptoms, increased intraocular pressure and mydriasis, as well as degeneration of retinal ganglion cells, optic nerve head excavation and reduction in optic nerve thickness, generalized severe irregularity of retinal vessels, faint presentation of choroidal vessels and severe optic nerve disc atrophy were all counteracted. In conclusion, we claim that the reversal of the episcleral veins cauterization glaucoma appeared as a consequence of the BPC 157 therapy of the vessel occlusion-induced perilous syndrome.

1 June 2007 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
SŠSanda Šitić
Sanda Šitić
PKPetra Korać
Petra Korać
PPPetra Peharec
Petra Peharec
GZGojko Zovko
Gojko Zovko
MPMarija Milković Periša
Marija Milković Periša
SGSlavko Gašparov
Slavko Gašparov

17 March 2017 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MPMarija Milković Periša
Marija Milković Periša
BSBozena Sarcevic
Bozena Sarcevic
KTKoraljka Gall Troselj
Koraljka Gall Troselj
KGKresimir Grsic
Kresimir Grsic
SSSanda Sitic
Sanda Sitic
SSSven Seiwerth
Sven Seiwerth
The expression of non-metastatic expressed/non-metastatic 23 nucleoside diphosphate kinase 1 (nm23-H1) and cyclooxygenase 2 (COX-2) proteins in thyroid carcinoma have been analysed in a number of previous studies, but this requires further study. The current study focused on the expression levels of nm23-H1 and COX-2 in 130 human thyroid papillary carcinoma (PTC) tissues. Of the 130 PTC tissues, 55 were classified as microcarcinoma and may provide information on the development of the specific characteristics of this tumour type. Routine histopathological examination and immunohistochemical detection of nm23-H1 and COX-2 expression was performed on 130 PTC tissues from patients treated in the Clinical Hospital for Tumours (Zagreb, Croatia) between January 2000 and December 2007. The stain intensity of nm23-H1 and COX-2 proteins was compared with the characteristics of the patients and the tumour. The highest overall expression rate of nm23-H1 and COX-2 was 90 and 67.6%, respectively, and the joint expression of these proteins was statistically significant. The median expression level of nm23-H1 was significantly increased in the classical and follicular histological group of the PTC tissues compared with tissues from other histological groups. The median expression level of COX-2 was significantly increased in the follicular histological group, and reduced in the diffuse-sclerosing group of PTC tissues. All the metastatic microcarcinoma tissues had increased expression levels of the two proteins in comparison with microcarcinoma tissues without lymph node metastases; however, this variation was only statistically significant for COX-2 expression levels. Therefore the results of the current study indicate that COX-2 protein levels may be able to differentiate which thyroid papillary microcarcinoma tumours possess metastatic potential.

13 December 2006 in Pathology International
Verified
Journal Article
Closed access
PDF file
ABAna Borovecki
Ana Borovecki
PKPetra Korać
Petra Korać
RVRoland A. Ventura
Roland A. Ventura
MPMarija Milković Periša
Marija Milković Periša
ABAlison H. Banham
Alison H. Banham
MDMara Dominis
Mara Dominis